Arcadia Biosciences, Inc. (RKDA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 11, 2026, and June 12, 2026. Arcadia Biosciences, Inc. entered into a Material Definitive Agreement to conduct a private placement of equity securities with an institutional accredited investor. The transaction closed on June 12, 2026.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $4 million (before deducting offering costs and expenses).
- Securities Issued:
- 3,883,496 Pre-Funded Warrants (exercise price $0.0001).
- 3,883,496 Series A-1 Preferred Investment Options (exercise price $0.91).
- 3,883,496 Series A-2 Preferred Investment Options (exercise price $0.91).
- Purchase Price: $1.0299 per Pre-Funded Warrant and accompanying Investment Options.
- Transaction Costs:
- Placement Agent Cash Fee: 7.0% of gross proceeds.
- Management Fee: 1.0% of gross proceeds.
- Expense Reimbursement: Up to $50,000 for legal and $25,000 for non-accountable expenses.
- Placement Agent Options: 271,845 options issued to H.C. Wainwright & Co., LLC at an exercise price of $1.2875.
Material Changes and Terms
The filing discloses a significant capital raise via a private placement. Key structural terms include:
- Exercise Restrictions: Holders are restricted from exercising securities if it would result in beneficial ownership exceeding 4.99% (or 9.99% at election) of outstanding Common Stock.
- Stockholder Approval: The Company must hold a stockholder meeting within 90 days of the Closing Date to obtain approval for the issuance of Series A-1 Investment Options. If not obtained, meetings must be called every 90 days thereafter.
- Registration Rights: The Company agreed to file a Resale Registration Statement within 15 days and use best efforts to have it declared effective within 45 days (or 75 days if a full review occurs).
- Lock-up Provisions: Restrictions on issuing new Common Stock or equivalents for 60 days post-registration effectiveness and a one-year ban on "Variable Rate Transactions."
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, revenue outlook, or management commentary on operational performance. The primary focus is the execution of the financing transaction.
Risks and Contingencies:
- Dilution: The issuance of Pre-Funded Warrants and Investment Options will increase the number of shares outstanding upon exercise.
- Registration Failure: Failure to meet filing deadlines for the Resale Registration Statement may result in damages payable to the Purchaser.
- Fundamental Transactions: In the event of a merger or asset sale, holders may be entitled to cash payments based on the Black-Scholes value of their options.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 8% total fees (7% cash + 1% management) and reimbursed expenses.
- Confirm the date and outcome of the required stockholder meeting for Series A-1 Investment Option approval.
- Review the effective date of the Resale Registration Statement to determine when the securities become freely tradable.
- Assess the potential dilution impact of the 3,883,496 Pre-Funded Warrants and 7,766,992 total Option Shares on current shareholders.
- Check for any subsequent filings regarding the "Variable Rate Transaction" restriction period.